Alexion, AstraZeneca’s Rare Disease group, indicated Thursday it plans to expand its presence in New Haven with space at the new bioscience tower currently under construction at 101 College St.
The company is headquartered in Boston, but has a New Haven presence, with roughly 500 employees working at its research facility at the existing tower next door, at 100 College St.